Onkologie. 2016:10(1):15-18 | DOI: 10.36290/xon.2016.005

Current status and prospects of targeted therapies non-small cell lung cancer

Martin Svatoň
Klinika pneumologie a ftizeologie, FN a LF UK Plzeň

Targeted chemotherapeutics and targeted biological therapy brought a significant shift in the treatment of NSCLC. These medicamnets

achieve higher efficiency in comparison with conventional chemotherapy with minor adverse effects. Moreover new

molecules demonstrate possibility to overcome resistance caused by first generation drugs. The paper described molecules already

in clinical use (that target sensitive EGFR mutation, ALK and ROS1 translocations and angiogensis inhibitors) as well as trends in

the near future in this field. New immunotherapeutic drugs are discussed in another article of this issue.

Keywords: targeted therapy, EGFR, ALK, ROS1, VEGF

Published: March 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Svatoň M. Current status and prospects of targeted therapies non-small cell lung cancer. Onkologie. 2016;10(1):15-18. doi: 10.36290/xon.2016.005.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Benesova L, Minarik M, Jancarikova D, et al. Multiplicity of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients treated with tyrosinekinase inhibitors. Anticancer Res 2010; 30(5): 1667-1671.
    2. Reungwetwattana T, Weroha SJ, Molina JR. Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC). Clin Lung Cancer 2012; 13(4): 252-266. Go to original source...
    3. Roberts PJ, Stinchcombe TE. KRAS mutation: should we test for it, and does it matter?. J Clin Oncol 2013; 31(8): 1112-1121. Go to original source... Go to PubMed...
    4. Mao C, Qiu LX, Liao RY, et. al. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies. Lung Cancer 2010; 69(3): 272-278. Go to original source... Go to PubMed...
    5. Roberts PJ, Stinchcombe TE, Der CJ, Socinski MA. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?. J Clin Oncol 2010; 28(31): 4769-4777. Go to original source... Go to PubMed...
    6. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2014; 350: 2129-2139. Go to original source... Go to PubMed...
    7. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500. Go to original source...
    8. Peters S, Adjei AA, Gridelli C, et al. Metastatic Non-Small-Cell Lung Cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2012; 23(Suppl 7): vii56-vii64. Go to original source...
    9. Yu Y, He J. Molecular classification of non-small-cell lung cancer: diagnosis, individualized treatment, and prognosis. Front Med 2013 - EPub. Go to original source... Go to PubMed...
    10. Savas P, Hughes B, Solomon B. Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer. J Thorac Dis 2013; 5(Suppl 5): S579-S592. Go to PubMed...
    11. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353(2): 123-32. Go to original source...
    12. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361(10): 947-957. Go to original source...
    13. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFRmutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13(3): 239-246. Go to original source...
    14. Svaton M, Pesek M, Chudacek Z, Vosmiková H. Current two EGFR mutations in lung adenocarcinoma - case report. Klin Onkol 2015; 28(2): 134-137. Go to original source... Go to PubMed...
    15. Solca F, Dahl G, Zoephel A, et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 2012; 343(2): 342-350. Go to original source... Go to PubMed...
    16. Liao BC, Lin CC, Yang JC. Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Curr Opin Oncol 2015; 27(2): 94-101. Go to original source... Go to PubMed...
    17. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31(27): 3327-3334. Go to original source... Go to PubMed...
    18. Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 2014; 15(2): 213-222. Go to original source...
    19. Yang JC, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 2015; 16(2): 141-151. Go to original source...
    20. Chen X, Zhu Q, Zhu L et al. Clinical perspective of afatinib in non-small cell lung cancer. Lung Cancer 2013; 81(2): 155-161. Go to original source... Go to PubMed...
    21. Yu HA, Arcila ME, Rekhtman N et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013; 19(8): 2240-2247. Go to original source...
    22. Xu M, Xie Y, Ni S, Liu H. The latest therapeutic strategies after resistance to first generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with non-small cell lung cancer (NSCLC). Ann Transl Med 2015; 3(7): 96.
    23. Eberlein CA, Stetson D, Markovets AA, et al. Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models. Cancer Res2015; 75(12): 2489-2500. Go to original source... Go to PubMed...
    24. Ercan D, Choi HG, Yun CH, et al. EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors. Clin Cancer Res 2015; 21(17): 3913-3923. Go to original source...
    25. Esposito A, Bardelli A, Criscitiello C, et al. Monitoring tumor-derived cell-free DNA in patients with solid tumors: clinical perspectives and research opportunities. Cancer Treat Rev; 40(5): 648-655.
    26. Sequist LV, Soria JC, Goldman JW, et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med 2015; 372(18): 1700-1709. Go to original source... Go to PubMed...
    27. Awad MM, Shaw AT. ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin Adv Hematol Oncol 2014; 12(7): 429-439.
    28. Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014; 370(13): 1189-1197. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.